Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 4/2015

01-04-2015 | Antiphospholipid Syndrome (D Erkan, Section Editor)

Difficult Clinical Situations in the Antiphospholipid Syndrome

Authors: Renata Ferreira Rosa, Michelle Remião Ugolini-Lopes, Audrey Krüse Zeinad-Valim, Elbio D’Amico, Danieli Andrade

Published in: Current Rheumatology Reports | Issue 4/2015

Login to get access

Abstract

Antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. However, there is a range of other manifestations associated with APS, called non-criteria manifestations that add significant morbidity to this syndrome and, some of them, represent difficult clinical situations to deal with. Other issues such as refractory treatment also represent challenging situations poorly addressed in the literature. Therefore, the purpose of this article is to review the management of difficult clinical situations in APS and provide information to help the readers in their decision-making process.
Literature
1.
Frances C. Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome. Lupus. 2010;19:1071–7.CrossRefPubMed
2.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and pattern of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.CrossRefPubMed
3.
Frances C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52(6):1785–93.
4.•
Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus. 2011;20(2):174–81. This article summarizes the studies on thrombocytopenia and skin manifestations and presents the recommendations elaborated by the Task Force. CrossRefPubMed
5.
Acland KM, Darvay A, Wakelin SH, et al. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140(1):131–5.CrossRefPubMed
6.
Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19(4):424–7.CrossRef
7.
Weinstein S, Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin N Am. 2008;22(1):67–77.CrossRef
8.
Kern AB. Atrophie blanche: report of two patients treated with aspirin and dipyridamole. J Am Acad Dermatol. 1982;6(6):1048–53.CrossRefPubMed
9.
Drucker CR, Duncan WC. Antiplatelet therapy in atrophie blanche and livedo vasculitis. J Am Acad Dermatol. 1982;7(3):359–63.CrossRefPubMed
10.
Rossini J, Roverano S, Graf C, et al. Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol. 2002;8:326–31.CrossRefPubMed
11.
Asherson RA, Francès C, Iaccarino L, et al. The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol. 2006;24:S46–51.PubMed
12.
Gertner E. Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. Lupus. 2003;12(2):133–5.CrossRefPubMed
13.
Srinivasan SK, Pittelkow MR, Cooper Jr LT. Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: a case report. Angiology. 2001;52(9):635–9.CrossRefPubMed
14.
Bounfour T, Bouaziz JD, Bézier M, et al. Intravenous immunoglobulins is difficult-to-treat ulcerated livedoid vasculopathy: five cases and review in literature. Int J Dermatol. 2013;52(9):1135–9.CrossRefPubMed
15.
Tenedios F, Erkan D, Lockshin MD. Rituximab in the primary antiphospholipid syndrome (PAPS). Arthritis Rheum. 2005;52:4078.
16.
Costa R, Fazal S, Kaplan RB, et al. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013;32:S79–82.CrossRefPubMed
17.•
Erkan D, Vega J, Ramón G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65(2):464–71. This is an uncontrolled and nonrandomized pilot study that suggests the safety and effectiveness of rituximab in aPL-positive patients in controlling some non-criteria manifestations of APS. CrossRefPubMed
18.
Uthman AT, Khamashta M. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum. 2006;35(6):360–7.CrossRefPubMed
19.
Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)—APS Nephropathy. Clin Rev Allergy Immunol. 2009;36:131–40.CrossRefPubMed
20.
Muhammed M, Nasri H. What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: is it time for formulating a classification for renal morphologic lesions? J Nephropathol. 2014;3(1):4–8.
21.
Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999;10:507–18.PubMed
22.
Amigo MC. Kidney disease in antiphospholipid syndrome. Rheum Dis Clin N Am. 2006;32:509–22.CrossRef
23.•
Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165–73. This article summarizes the studies on the catastrophic APS, APS nephropathy and heart valve lesions, and presents recommendations elaborated by the Task Force. CrossRefPubMed
24.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMed
25.
Moss KE, Isenberg DA. Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology (Oxford). 2001;40(8):863–7.CrossRef
26.
Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol. 2002;13(1):42–52.
27.
Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol. 2008;35(10):1983–8.PubMed
28.
Fakhouri F, Noel LH, Zuber J, et al. The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis. 2003;41:1205–11.CrossRefPubMed
29.
Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50:2569–79.CrossRefPubMed
30.
Dayal NA, Isenberg DA. Endstage renal failure in primary antiphospholipid syndrome-case report and review of literature. Rheumatology (Oxford). 2003;42:1128–9.CrossRef
31.
Korkmaz C, Kabukcuoglu S, Isiksoy S, et al. Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy. Lupus. 2003;12:760–5.CrossRefPubMed
32.
Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2009;5:160–70.CrossRefPubMed
33.
Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC. 2013;11:95.CrossRef
34.•
Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279–89. This review resume all aspects of renal involvement in antiphospholipid syndrome.CrossRefPubMed
35.
Velik-Salchner C, Lederer W, Wiedermann F. Eculizumab and renal transplantation in a patient with catastrophic antiphospholipid syndrome: effect of heparin on complement activation. Lupus. 2011;20:772.CrossRefPubMed
36.••
Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. This article systematically reviews the potential future treatment strategies for aPL-positive patients.CrossRefPubMed
37.
Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the Antiphospholipid Syndrome. N Engl J Med. 2014;371:303–12.CrossRefPubMed
38.
Eikelboom JW, Weitz JI. The mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371(4):369–71.CrossRefPubMed
39.
Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholid syndrome. Lupus. 2005;14:691–6.CrossRefPubMed
40.
Long BR, Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am. 2008;22:79–94.CrossRefPubMed
41.
Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J Autoimmun. 2005;15:123–5.CrossRef
42.
Espinola-Zavaleta N, Vargas-Barron J, Colmenares-Galvis T, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J. 1999;137:974–9.CrossRef
43.
Zuily S, Regnault V, Selton-Suty C, et al. Increased Risk for Heart Valve Disease Associated With Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus: Meta-Analysis of Echocardiographic P Circulation 2011;124:215–224.
44.
Espinola-Zavaleta N, Montes RM, Soto ME, et al. Primary antiphospholipidsyndrome: a 5 year transesophageal echocardiographic follow up study. J Rheumatol. 2004;31:2402–7.
45.
Morita H, Daido H, Suwa T, et al. Overt congestive heart failure with mitral and aortic regurgitation due to antiphospholipid syndrome in a patient with systemic lupus erythematosus. Intern Med. 2000;39:506–11.CrossRefPubMed
46.•
Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414–20. This article alerts that valve replacement in patients with APS carry significant early and late morbidity and mortality.CrossRefPubMed
47.
Erdozain J-G, Ruiz-Irastorza G, Segura M-I, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res. 2012;64:1256–60.
48.
Bert JS, Abdullah M, Dahle TG, et al. Transcatheter aortic valve replacement for advanced valvular disease in active SLE and APS. Lupus. 2013;22:1046. originally published online 24 July 2013.CrossRefPubMed
49.
Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 2003;42:200–13.CrossRefPubMed
50.
Sanna G, D’Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin N Am. 2006;32:465–90.CrossRef
51.
Jacobson MW, Rapport LJ, Keenan PA, et al. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21:251–64.CrossRefPubMed
52.
Denburg SD, Carbotte RM, Ginsberg JS, et al. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997;3:377–86.
53.
Menon S, Jamenson-Shortall E, Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–41.CrossRefPubMed
54.
Hanly JG, Walsh NM, Fisk JD, et al. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol. 1993;32:291–6.CrossRefPubMed
55.
Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166:2278–84.CrossRefPubMed
56.
Kozora E, Erkan D, Zhang L, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exp Rheumatol. 2014;32(1):34–40.PubMed
57.
Appenzeller S, Lapa AT, Carvalho JF, et al. Cognitive dysfunction in antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14:95–8.CrossRef
58.
Appenzeller S, Lapa AT, Guirau CR, et al. Cognitive impairment in antiphospholipid syndrome: evidence from animals models. Clin Rheumatol. 2012;31:403–6.CrossRefPubMed
59.
Alarcón-Segovia D, Cabral AR. Antiphospholipid antibodies. Where do they come from? Where do they go? J Rheumatol. 1994;21(6):982–9.PubMed
60.
Macchi L, Rispal P, Clofent-Sanchez G, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol. 1997;98(2):336–41.CrossRefPubMed
61.
Atsumi T, Furukawa S, Amengual O, et al. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14(7):499–504.CrossRefPubMed
62.
63.
Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica. 1997;82(1):101–5. Review.PubMed
64.•
Forastiero R. Bleeding in the antiphospholipid syndrome. Hematology. 2012;17 Suppl 1:S153–5. This review alerts that bleeding is uncommon but can be the first clinical manifestation in patients having severe thrombocytopenia or prothrombin deficiency.PubMed
65.
Kavanaugh A. Danazol therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Intern Med. 1994;121(10):767–8.CrossRefPubMed
66.
Alarcón-Segovia D, Sánchez-Guerrero J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol. 1989;16(10):1359–61.PubMed
67.
Durand JM, Lefevre P, Kaplanski G, et al. Correction of thrombocytopenia with dapsone in the primary antiphospholipid syndrome. J Rheumatol. 1993;20(10):1777–8.PubMed
68.
Suarez IM, Diaz RA, Aguayo Canela D, et al. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus. 1996;5(1):81–3.PubMed
69.
Pons I, Espinosa G, Cervera R. Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review. Med Clin (Barc). 2015;144(3):97–104.
70.
Delgado Alves J, Inanc M, Diz-Kucukkaya R, et al. Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. Eur J Intern Med. 2004;15(3):162–7.CrossRefPubMed
71.
Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33.CrossRefPubMed
72.
Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237–42.CrossRefPubMed
73.
Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Ann Rheum Dis. 2009;68(9):1428–32.CrossRefPubMed
74.•
Nalli C, Andreoli L, Casu C, et al. Management of recurrent thrombosis in antiphospholipid syndrome. Curr Rheumatol Rep. 2014;16(3):405. This review resume strategies for optimizing therapy for APS patients with recurrent thrombosis.CrossRefPubMed
75.
Scoble T, Wijetilleka S, Khamashta MA. Management of refractory anti-phospholipid syndrome. Autoimmun Rev. 2011;10(11):669–73.CrossRefPubMed
76.
Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–8.CrossRefPubMed
77.
Dentali F, Crowther M, Ageno W, et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005;3(9):2121–3.
78.
Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, et al. Ann Rheum Dis. 2011;70(9):1652–4.
79.
Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18.CrossRefPubMed
80.
Espinola RG, Pierangeli SS, Gharavi AE, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antiodies. Thromb Haemost. 2002;87(3):518–22.PubMed
81.
Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96(12):4380–4.CrossRefPubMed
82.
Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687–95.CrossRefPubMedCentralPubMed
83.
Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19(4):486–91.CrossRefPubMed
84.
Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73(6):1176–80.CrossRefPubMed
85.
Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64(8):2719–23.CrossRefPubMed
86.
Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14(2):459–65.CrossRefPubMed
87.
Schaefer JK, McBane RD, Black DF, et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost. 2014;14:112(5).
88.
Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factor for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32.CrossRefPubMed
89.
Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998–1005.CrossRefPubMed
90.
Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the Global Antiphospholipid Syndrome Score (GAPSS) in a prospective cohort. Arthritis Care Res. 2014;66(12):1915–20.CrossRef
Metadata
Title
Difficult Clinical Situations in the Antiphospholipid Syndrome
Authors
Renata Ferreira Rosa
Michelle Remião Ugolini-Lopes
Audrey Krüse Zeinad-Valim
Elbio D’Amico
Danieli Andrade
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 4/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0502-7

Other articles of this Issue 4/2015

Current Rheumatology Reports 4/2015 Go to the issue

Orphan Diseases (B Manger, Section Editor)

Rheumatic Manifestations of Scurvy

Rheumatoid Arthritis (L Moreland, Section Editor)

Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials

Antiphospholipid Syndrome (D Erkan, Section Editor)

Pediatric Antiphospholipid Syndrome

Vasculitis (LR Espinoza, Section Editor)

Cogan’s Syndrome and Other Ocular Vasculitides

Vasculitis (L Espinoza, Section Editor)

Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?

Surgery and Perioperative Care (CR MacKenzie and SM Goodman, Section Editors)

Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits